In vivo validation of the mutant selection window hypothesis with moxifloxacin in a murine model of tuberculosis

Deepak Almeida, Eric Nuermberger, Sandeep Tyagi, William Ramses Bishai, Jacques Grosset

Research output: Contribution to journalArticle

Abstract

Combination therapy is the most effective strategy to prevent emergence of resistance during tuberculosis (TB) treatment. Another strategy, albeit theoretical, is to limit the time that drug concentrations fall in the "mutant selection window" (MSW) between the MIC and the mutant prevention concentration (MPC). Drug concentrations above the MPC prevent selective amplification of resistant mutants in vitro even with a single drug exposure. The MSW concept has been validated using fluoroquinolones against Mycobacterium tuberculosis in vitro but not in vivo. Using a mouse model in which serum moxifloxacin (MXF) concentrations were maintained above the MPC, we tested whether this strategy prevents selection of MXF-resistant mutants. Beginning 2 weeks after aerosol infection with M. tuberculosis, when the mean lung log10 CFU count was 7.9 ± 0.2, mice received either no treatment or MXF in the diet at 0.25% to approximate the conventional human dose or 1.5% to maintain serum concentrations above the MPC (8 μg/ml). After 56 days of treatment, lung CFU counts were 3.5 ± 0.8 and 0.9 ± 0.6 in 0.25% and 1.5% of the MXF-treated mice, respectively. In mice given 0.25% MXF, MXF-resistant mutants were selected by day 28 and detected in 16% (3/19) of mice tested on day 56. No selection of MXF-resistant mutants was detected in mice given 1.5% MXF. We conclude that maintaining serum concentrations of MXF above the MPC prevents selection of MXF-resistant mutants. Although this target cannot be achieved clinically with MXF, it might be possible with new fluoroquinolones with more potent activity and/or improved pharmacokinetics.

Original languageEnglish (US)
Pages (from-to)4261-4266
Number of pages6
JournalAntimicrobial Agents and Chemotherapy
Volume51
Issue number12
DOIs
StatePublished - Dec 2007

Fingerprint

Tuberculosis
Fluoroquinolones
Mycobacterium tuberculosis
moxifloxacin
Serum
Pharmaceutical Preparations
Lung
Aerosols
Pharmacokinetics
Diet
Infection

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

In vivo validation of the mutant selection window hypothesis with moxifloxacin in a murine model of tuberculosis. / Almeida, Deepak; Nuermberger, Eric; Tyagi, Sandeep; Bishai, William Ramses; Grosset, Jacques.

In: Antimicrobial Agents and Chemotherapy, Vol. 51, No. 12, 12.2007, p. 4261-4266.

Research output: Contribution to journalArticle

@article{10545f9af3164cc48450f761f3a39d80,
title = "In vivo validation of the mutant selection window hypothesis with moxifloxacin in a murine model of tuberculosis",
abstract = "Combination therapy is the most effective strategy to prevent emergence of resistance during tuberculosis (TB) treatment. Another strategy, albeit theoretical, is to limit the time that drug concentrations fall in the {"}mutant selection window{"} (MSW) between the MIC and the mutant prevention concentration (MPC). Drug concentrations above the MPC prevent selective amplification of resistant mutants in vitro even with a single drug exposure. The MSW concept has been validated using fluoroquinolones against Mycobacterium tuberculosis in vitro but not in vivo. Using a mouse model in which serum moxifloxacin (MXF) concentrations were maintained above the MPC, we tested whether this strategy prevents selection of MXF-resistant mutants. Beginning 2 weeks after aerosol infection with M. tuberculosis, when the mean lung log10 CFU count was 7.9 ± 0.2, mice received either no treatment or MXF in the diet at 0.25{\%} to approximate the conventional human dose or 1.5{\%} to maintain serum concentrations above the MPC (8 μg/ml). After 56 days of treatment, lung CFU counts were 3.5 ± 0.8 and 0.9 ± 0.6 in 0.25{\%} and 1.5{\%} of the MXF-treated mice, respectively. In mice given 0.25{\%} MXF, MXF-resistant mutants were selected by day 28 and detected in 16{\%} (3/19) of mice tested on day 56. No selection of MXF-resistant mutants was detected in mice given 1.5{\%} MXF. We conclude that maintaining serum concentrations of MXF above the MPC prevents selection of MXF-resistant mutants. Although this target cannot be achieved clinically with MXF, it might be possible with new fluoroquinolones with more potent activity and/or improved pharmacokinetics.",
author = "Deepak Almeida and Eric Nuermberger and Sandeep Tyagi and Bishai, {William Ramses} and Jacques Grosset",
year = "2007",
month = "12",
doi = "10.1128/AAC.01123-07",
language = "English (US)",
volume = "51",
pages = "4261--4266",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "12",

}

TY - JOUR

T1 - In vivo validation of the mutant selection window hypothesis with moxifloxacin in a murine model of tuberculosis

AU - Almeida, Deepak

AU - Nuermberger, Eric

AU - Tyagi, Sandeep

AU - Bishai, William Ramses

AU - Grosset, Jacques

PY - 2007/12

Y1 - 2007/12

N2 - Combination therapy is the most effective strategy to prevent emergence of resistance during tuberculosis (TB) treatment. Another strategy, albeit theoretical, is to limit the time that drug concentrations fall in the "mutant selection window" (MSW) between the MIC and the mutant prevention concentration (MPC). Drug concentrations above the MPC prevent selective amplification of resistant mutants in vitro even with a single drug exposure. The MSW concept has been validated using fluoroquinolones against Mycobacterium tuberculosis in vitro but not in vivo. Using a mouse model in which serum moxifloxacin (MXF) concentrations were maintained above the MPC, we tested whether this strategy prevents selection of MXF-resistant mutants. Beginning 2 weeks after aerosol infection with M. tuberculosis, when the mean lung log10 CFU count was 7.9 ± 0.2, mice received either no treatment or MXF in the diet at 0.25% to approximate the conventional human dose or 1.5% to maintain serum concentrations above the MPC (8 μg/ml). After 56 days of treatment, lung CFU counts were 3.5 ± 0.8 and 0.9 ± 0.6 in 0.25% and 1.5% of the MXF-treated mice, respectively. In mice given 0.25% MXF, MXF-resistant mutants were selected by day 28 and detected in 16% (3/19) of mice tested on day 56. No selection of MXF-resistant mutants was detected in mice given 1.5% MXF. We conclude that maintaining serum concentrations of MXF above the MPC prevents selection of MXF-resistant mutants. Although this target cannot be achieved clinically with MXF, it might be possible with new fluoroquinolones with more potent activity and/or improved pharmacokinetics.

AB - Combination therapy is the most effective strategy to prevent emergence of resistance during tuberculosis (TB) treatment. Another strategy, albeit theoretical, is to limit the time that drug concentrations fall in the "mutant selection window" (MSW) between the MIC and the mutant prevention concentration (MPC). Drug concentrations above the MPC prevent selective amplification of resistant mutants in vitro even with a single drug exposure. The MSW concept has been validated using fluoroquinolones against Mycobacterium tuberculosis in vitro but not in vivo. Using a mouse model in which serum moxifloxacin (MXF) concentrations were maintained above the MPC, we tested whether this strategy prevents selection of MXF-resistant mutants. Beginning 2 weeks after aerosol infection with M. tuberculosis, when the mean lung log10 CFU count was 7.9 ± 0.2, mice received either no treatment or MXF in the diet at 0.25% to approximate the conventional human dose or 1.5% to maintain serum concentrations above the MPC (8 μg/ml). After 56 days of treatment, lung CFU counts were 3.5 ± 0.8 and 0.9 ± 0.6 in 0.25% and 1.5% of the MXF-treated mice, respectively. In mice given 0.25% MXF, MXF-resistant mutants were selected by day 28 and detected in 16% (3/19) of mice tested on day 56. No selection of MXF-resistant mutants was detected in mice given 1.5% MXF. We conclude that maintaining serum concentrations of MXF above the MPC prevents selection of MXF-resistant mutants. Although this target cannot be achieved clinically with MXF, it might be possible with new fluoroquinolones with more potent activity and/or improved pharmacokinetics.

UR - http://www.scopus.com/inward/record.url?scp=36749021610&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36749021610&partnerID=8YFLogxK

U2 - 10.1128/AAC.01123-07

DO - 10.1128/AAC.01123-07

M3 - Article

VL - 51

SP - 4261

EP - 4266

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 12

ER -